Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03483038 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Adenocarcinoma, sponsored by University of Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT03483038 is a Phase 2 study of Pancreatic Adenocarcinoma that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 45 participants, below the 99,464-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03483038, a Phase 2 study of Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase II, single arm, non-randomized, open label study of liposomal irinotecan with FOLFOX in the neoadjuvant setting in patients with resectable or borderline resectable, previously untreated pancreatic adenocarcinoma. The primary objective of this study is to investigate the safety and feasibility of this treatment regimen in this patient population.
Conditions Studied
Interventions
- DRUG FOLFOX regimen
- DRUG Liposomal Irinotecan
Study Locations (4)
Florida
- University of Florida - Gainesville
- Orlando Health UF Health Cancer Center - Orlando
- Tallahassee Memorial Health Care - Tallahassee
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03483038
The ClinicalTrials.gov registry entry for NCT03483038 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,464-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which FOLFOX regimen is the first listed.
NCT03483038 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT03483038 about?
NCT03483038 is a clinical study titled "A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma". This is a phase II, single arm, non-randomized, open label study of liposomal irinotecan with FOLFOX in the neoadjuvant setting in patients with resectable or borderline resectable, previously untreated pancreatic adenocarcinoma. The primary objective of this study is to investigate the safety and f...
What is the current status of trial NCT03483038?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2018-12-13. Estimated completion is 2026-12.
What conditions does trial NCT03483038 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT03483038?
The interventions under investigation include: FOLFOX regimen (DRUG), Liposomal Irinotecan (DRUG).
Who is sponsoring clinical trial NCT03483038?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03483038 being conducted?
This trial has 4 study locations across Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.